Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer

NCT01610869 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT01610869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01610869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2014
Completion date
January 11, 2018
Enrollment
117 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer